Cataract surgery and its complications in diabetic patients

Seminars in Ophthalmology

Volumn 29, Issue 5-6, 2014, Pages 329-337

  Haddad, Nour Maya N ^a   Sun, Jennifer K ^a,b   Abujaber, Samer ^c   Schlossman, Deborah K ^a   Silva, Paolo S ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cataract; Complications; Diabetes; Diabetic macula edema; Diabetic retinopathy

Indexed keywords

BALANCED SALT SOLUTION; BEVACIZUMAB; DEXAMETHASONE; KETOROLAC; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

CATARACT; CATARACT EXTRACTION; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; LENS IMPLANT; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PROPHYLAXIS; PROTEINURIA; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK FACTOR; STEROID THERAPY; TREATMENT INDICATION; VISUAL ACUITY; ADVERSE EFFECTS; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY;

CATARACT; CATARACT EXTRACTION; DIABETES COMPLICATIONS; DISEASE PROGRESSION; HUMANS; RISK FACTORS;

EID: 84912035430     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2014.959197     Document Type: Review

References (82)

1. International Diabetes Federation. IDF Diabetes Atlas, 6th ed.; Brussels: International Diabetes Federation, 2013. Available at: http://www.idf.org/diabetesatlas
2. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136(1):122-135.
3. Erie JC. Rising cataract surgery rates: demand and supply. Ophthalmology 2014;121(1):2-4.
4. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012;96(5):614-8.
5. Hashim Z, Zarina S. Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr) 2011;33(3):377-84.
6. Sensi M, Pricci F, Pugliese G, et al. Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res Clin Pract 1995;28(1):9-17. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7587917
7. Ramalho J, Marques C, Pereira P, Mota MC. Crystallin composition of human cataractous lens may be modulated by protein glycation. Graefes Arch Clin Exp Ophthalmol 1996; 234 Suppl:S232-8. Available at: http://www.ncbi.nlm.nih. gov/pubmed/8871180
8. Olafsdottir E, Andersson DKG, Stefánsson E. The prevalence of cataract in a population with and without type 2 diabetes mellitus. Acta Ophthalmol 2012;90(4):334-40.
9. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract: Pathogenesis, epidemiology and treatment. J Ophthalmol 2010;2010:608751.
10. Pinarci EY, Bayar SA, Sizmaz S, Yesilirmak N, Akkoyun I, Yilmaz G. Anterior segment complications after phacovitrectomy in diabetic and nondiabetic patients. Eur J Ophthalmol 2013;23(2):223-9.
11. Takamura Y, Tomomatsu T, Arimura S, et al. Anterior capsule contraction and flare intensity in the early stages after cataract surgery in eyes with diabetic retinopathy. J Cataract Refract Surg 2013;39(5):716-21.
12. Greenberg PB, Tseng VL, Wu WC, et al. Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans. Ophthalmology 2011; 118(3):507-14.
13. Flesner P, Sander B, Henning V, Parving HH, Dornonville de la Cour M, Lund-Andersen H. Cataract surgery on diabetic patients: A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand 2002; 80(1):19-24. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11906299
14. Dowler JG, Hykin PG, Lightman SL, Hamilton AM. Visual acuity following extracapsular cataract extraction in diabetes: A meta-Analysis. Eye (Lond) 1995;9(Pt 3):313-7.
15. Menchini U, Bandello F, Brancato R, Camesasca FI, Galdini M. Cystoid macular oedema after extracapsular cataract extraction and intraocular lens implantation in diabetic patients without retinopathy. Br J Ophthalmol 1993; 77(4):208-11. Available at: http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=504482&tool=pmcentrez &rendertype=abstract
16. Pollack A, Leiba H, Bukelman A, Abrahami S, Oliver M. The course of diabetic retinopathy following cataract surgery in eyes previously treated by laser photocoagulation. Br J Ophthalmol 1992;76(4):228-31. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=504234&tool=pmcentrez&rendertype=abstract
17. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology 2007; 114(5):881-9.
18. Patel JI, Hykin PG, Cree Ia. Diabetic cataract removal: Postoperative progression of maculopathy: Growth factor and clinical analysis. Br J Ophthalmol 2006;90(6):697-701.
19. Ostri C, Lux A, Lund-Andersen H, la Cour M. Long-term results, prognostic factors and cataract surgery after diabetic vitrectomy: A 10-year follow-up study. Acta Ophthalmol 2014;92(6):571-6.
20. Ostri C, Lund-Andersen H, Sander B, La Cour M. Phacoemulsification cataract surgery in a large cohort of diabetes patients: Visual acuity outcomes and prognostic factors. J Cataract Refract Surg 2011;37(11):2006-12.
21. Gupta A, Gupta V. Diabetic maculopathy and cataract surgery. Ophthalmol Clin North Am 2001;14(4):625-37. Available at: http://www.pubmedcentral.nih.gov/article render.fcgi?artid=1771134&tool=pmcentrez&rendertype =abstract.
22. Klein BE, Klein R, Moss SE. Prevalence of cataracts in a population-based study of persons with diabetes mellitus. Ophthalmology 1985 Sep;92(9):1191-6.
23. Rim THT, Kim M-H, Kim WC, Kim T-I, Kim EK. Cataract subtype risk factors identified from the Korea National Health and Nutrition Examination survey 2008-2010. BMC Ophthalmol 2014;14:4.
24. Leske MC, Wu S-Y, Nemesure B, Hennis A. Risk factors for incident nuclear opacities. Ophthalmology 2002; 109(7):1303-8. Available at: http://www.ncbi.nlm.nih.-gov/pubmed/12093655
25. Hennis A, Wu S-Y, Nemesure B, Leske MC. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 2004; 122(4):525-30.
26. Klein BE, Klein R, Lee KE. Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: The Beaver Dam Eye Study. Am J Ophthalmol 1998;126(6):782-90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9860001
27. Kanthan GL, Mitchell P, Burlutsky G, Wang JJ. Fasting blood glucose levels and the long-term incidence and progression of cataract: The Blue Mountains Eye Study. Acta Ophthalmol 2011;89(5):e434-8.
28. Richter GM, Choudhury F, Torres M, Azen SP, Varma R. Risk factors for incident cortical, nuclear, posterior subcapsular, and mixed lens opacities: The Los Angeles Latino eye study. Ophthalmology 2012;119(10):2040-7.
29. Stevens A. The contribution of glycation to cataract formation in diabetes. J Am Optom Assoc 1998; 69(8):519-30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9747048
30. Nagaraj RH, Sady C. The presence of a glucose-derived Maillard reaction product in the human lens. FEBS Lett 1996;382(3):234-8. Available at: http://www.ncbi.nlm.nih.-gov/pubmed/8605976
31. Nagaraj RH, Monnier VM. Isolation and characterization of a blue fluorophore from human eye lens crystallins: In vitro formation from Maillard reaction with ascorbate and ribose. Biochim Biophys Acta 1992;1116(1):34-42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1540622
32. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324(Pt 2):565-70. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1218467&tool=pmcentrez&rendertype=abstract
33. Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids 2012; 42(4):1205-20.
34. Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 2004;4(1):31-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14764277
35. Datiles MB, Kador PF. Type I diabetic cataract. Arch Ophthalmol 1999;117(2):284-5. Available at: http://www. ncbi.nlm.nih.gov/pubmed/10037586
36. Kumamoto Y, Takamura Y, Kubo E, Tsuzuki S, Akagi Y. Epithelial cell density in cataractous lenses of patients with diabetes: Association with erythrocyte aldose reductase. Exp Eye Res 2007;85(3):393-9.
37. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. Br J Ophthalmol 1996; 80(9):789-93. Available at: http://www.pubmedcentral.-nih.gov/articlerender.fcgi?artid=505613&tool=pmcentrez &rendertype=abstract
38. Stein J. Serious adverse events after cataract surgery. Curr Opin Ophthalmol 2012 May;23(3):219-225.
39. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995;113(8):1019-29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7639652
40. Kim SJ, Belair M-L, Bressler NM, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina 2008;28(6):870-6.
41. Chew EY, Benson WE, Remaley NA, et al. Results after lens extraction in patients with diabetic retinopathy. Arch Ophthalmol 1999;117:1600-1606.
42. Cetin EN, Yldrm C. Adjuvant treatment modalities to control macular edema in diabetic patients undergoing cataract surgery. Int Ophthalmol 2013;33(5):605-10.
43. Davis MD, Fisher R, Gangnon RE, et al. Risk factors for high-risk prolifer ative diabetic retinopathy and severe visual loss. Invest Ophthalmol Vis Sci 1998;39(2):233-52.
44. Aiello LM, Wand M, Liang G. Neovascular glaucoma and vitreous hemorrhage following cataract surgery in patients with diabetes mellitus. Ophthalmology 1983;90(7):814-20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6194491
45. Benson WE, Brown GC, Tasman W, McNamara JA, Vander JF. Extracapsular cataract extraction with placement of a posterior chamber lens in patients with diabetic retinopathy. Ophthalmology 1993;100(5):730-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8493017
46. UK Prospective Diabetes Study (UKPDS 33). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9742976
47. The Diabetes Control and Complications Trial. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol 1995;113(1):36-51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7826293
48. Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol Scand 1996;74(6):523-7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9017034
49. Krepler K, Biowski R, Schrey S, Jandrasits K, Wedrich A. Cataract surgery in patients with diabetic retinopathy: Visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2002;240:735-8.
50. Mackool RJ. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol 1993;115(3):400-2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8442509
51. Stein JD, Grossman DS, Mundy KM, Sugar A, Sloan FA. Severe adverse events after cataract surgery among medicare beneficiaries. Ophthalmology 2011;118(9):1716-23.
52. Narendran N, Jaycock P, Johnston RL, et al. The Cataract National Dataset electronic multicentre audit of 55,567 operations: Risk stratification for posterior capsule rupture and vitreous loss. Eye (Lond) 2009;23(1):31-7.
53. Moriarty AP, Spalton DJ, Moriarty BJ, Shilling JS, Ffytche TJ, Bulsara M. Studies of the blood-Aqueous barrier in diabetes mellitus. Am J Ophthalmol 1994;117(6):768-71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8198161
54. Ebihara Y, Kato S, Oshika T, Yoshizaki M, Sugita G. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. J Cataract Refract Surg 2006; 32(7):1184-7.
55. Hayashi K, Hayashi H, Nakao F, Hayashi F. Posterior capsule opacification after cataract surgery in patients with diabetes mellitus. Am J Ophthalmol 2002;134(1):10-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12095802
56. Zaczek A, Zetterström C. Posterior capsule opacification after phacoemulsification in patients with diabetes mellitus. J Cataract Refract Surg 1999;25(2):233-7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9951670
57. Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Arch Ophthalmol 2000;118(7):912-7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10900103
58. Liao S-B, Ku W-C. Progression of diabetic retinopathy after phacoemulsification in diabetic patients: A three-year analysis. Chang Gung Med J 2003;26(11):829-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14765753
59. Romero-Aroca P, Fernández-Ballart J, Almena-Garcia M, Méndez-Maŕn I, Salvat-Serra M, Buil-Calvo JA. Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: Prospective study. J Cataract Refract Surg 2006;32:1438-1444.
60. Squirrell D, Bhola R, Bush J, Winder S, Talbot JF. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol 2002;86(5):565-71. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi artid=1771134&tool=pmcentrez&rendertype=abstract
61. Hong T, Mitchell P, de Loryn T, Rochtchina E, Cugati S, Wang JJ. Development and progression of diabetic retinopathy 12 months after phacoemulsification cataract surgery. Ophthalmology 2009;116(8):1510-4.
62. Eriksson U, Alm A, Bjärnhall G, Granstam E, Matsson AW. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmol 2011;249(3):349-59.
63. Kwon SI, Hwang DJ, Seo JY, Park IW. Evaluation of changes of macular thickness in diabetic retinopathy after cataract surgery. Korean J Ophthalmol 2011;25(4):238-42.
64. Dowler JG, Sehmi KS, Hykin PG, Hamilton AM. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999;106(4):663-8.
65. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21(7):1131-7.
66. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema: Risk factors for development and duration after treatment. J Cataract Refract Surg 2007; 33(9):1550-8.
67. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012; 6:1259-69.
68. Elsawy MF, Badawi N, Khairy HA. Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clin Ophthalmol 2013;7: 1245-9.
69. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, Navea-Tejerina A. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: A pilot study. Retina 2009;29(4):530-5.
70. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009; 116(6):1151-7.
71. Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. J Cataract Refract Surg 2009;35:18-25.
72. Akinci A, Batman C, Ozkilic E, Altinsoy A. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract. Retina 2009;29(10):1432-5.
73. Wahab S, Ahmed J. Management of cataract with macular oedema due to diabetes mellitus type-II and hypertension with grid laser prior to surgery and intra-vitreal bevacizumab (Avastin) peroperatively. J Pak Med Assoc 2010; 60(10):836-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21381615
74. Fard MA, Yazdanei Abyane A, Malihi M. Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: Prospective randomized study. Eur J Ophthalmol 2011;21(3):276-81. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20853269.
75. Rauen PI, Ribeiro JAS, Almeida FPP, Scott IU, Messias A, Jorge R. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina 2012;32(9):1799-803.
76. Udaondo P, Garcia-Pous M, Garcia-Delpech S, Salom D, Diaz-Llopis M. Prophylaxis of macular edema with intravitreal ranibizumab in patients with diabetic retinopathy after cataract surgery: A pilot study. J Ophthalmol 2011; 2011(September 2010):159436.
77. Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina 2014;34(1):149-56.
78. Lam DSC, Chan CKM, Mohamed S, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: A 6-month prospective pilot study. Eye (Lond) 2005;19(8):885-90.
79. Chew EY, Glassman AR, Beck RW, et al. Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina 2011; 31(2):284-289.
80. Takata C, Messias A, Folgosa MS, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina 2010; 30(4):562-9.
81. Habib MS, Cannon PS, Steel DHW. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract. BMC Ophthalmol 2005;5:15.
82. Kim S-Y, Yang J, Lee Y-C, Park Y-H. Effect of a single intraoperative sub-Tenon injection of triamcinolone acetonide on the progression of diabetic retinopathy and visual outcomes after cataract surgery. J Cataract Refract Surg 2008; 34(5):823-6.